Skip to content


Onglyza (saxagliptin) is a small molecule pharmaceutical. Saxagliptin was first approved as Onglyza on 2009-07-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Onglyza's patents are valid until 2028-11-30 (FDA).
Trade Name Onglyza
Common Name Saxagliptin
Indication type 2 diabetes mellitus
Drug Class Dipeptidyl aminopeptidase-IV inhibitors
Get full access now